Clinical Trial Update: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial of masitinib in severe Indolent Systemic Mastocytosis unresponsive to optimal symptomatic treatment is underway, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Indolent Systemic Mastocytosis | Phase 3 | Status: UNKNOWN